|
A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma
RECRUITINGPhase 2Sponsored by Memorial Sloan Kettering Cancer Center
Actively Recruiting
PhasePhase 2
SponsorMemorial Sloan Kettering Cancer Center
Started2024-06-27
Est. completion2026-06
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT06485778
Summary
This study will test whether limiting standard photon intensity modulated radiation therapy (IMRT) to exclude the oral tongue surgical site can decrease the risk of side effects caused by oral radiation. The researchers will also find out if this approach affects the rate of disease coming back after treatment (recurrence), and will measure participants' quality of life by having them complete questionnaires.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:
* Age ≥ 18
* Surgical resection of all gross disease without evidence of residual loco-regional disease on simulation PET/CT.
* pT1-2, or pT3 by DOI, pN0-2b Squamous Cell Carcinoma of the Oral Tongue confirmed on final surgical pathology. Patients must have:
* at least two of the following pathologic risk features
* LVI
* DOI ≥ 4mm and ≤ 10mm OR
* 1 or 2 pathologically positive nodes N1 to low volume N2b. OR DOI \>10 mm OR
* \<=cT3N2b who undergo induction with near pCR (\<5% viable) or pCR at primary site
* Primary specimen surgical margins ≥3 mm (if \<WPOI 5, margin can be \>= 2.2mm)
* Signed informed consent form by the participant or their legally authorized representative (LAR)
Exclusion Criteria:
* N2c/N3 nodal disease
* pT3 by size
* \>2 pathologically positive nodes
* Primary specimen surgical margin \< 3 mm
* Extensive Perineural Invasion (PNI); non-extensive PNI is permitted.
* Extra-capsular extension in any pathologically positive lymph node
* Prior or simultaneous invasive malignancy that, in the opinion of the PI, represents a competing risk of death equivalent to the patient's oral tongue squamous cell carcinoma.
* Auto-immune conditions that would otherwise preclude radiation in the opinion of the PI (e.g. Scleroderma).
* Lack of ability to understand and willingness to sign a written informed consent and complete questionnaires.Conditions2
CancerOral Tongue Squamous Cell Carcinoma
Locations7 sites
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
Sean McBride, MD, MPH646-608-2450
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
Sean McBride, MD646-608-2450
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645
Sean McBride, MD646-608-2450
Memorial Sloan Kettering Suffolk - Commack
Commack, New York, 11725
Sean McBride, MD646-608-2450
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
Sean McBride, MD646-608-2450
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorMemorial Sloan Kettering Cancer Center
Started2024-06-27
Est. completion2026-06
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT06485778